Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
TechSpot means tech analysis and advice you can trust. When you buy through our links, we may earn a commission. TL;DR: If you're looking for a powerful productivity suite without recurring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback